Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer pays $49.8mm for remainder of partner Icagen

Executive Summary

In its second recent acquisition to build up pain management capabilities, Pfizer Inc. is buying public ion channel modulation firm Icagen Inc. The Big Pharma will pay $6 per share (a 9% discount) for the 89% of Icagen’s shares (approximately 8.3mm) that it didn’t already own, amounting to a total of $49.8mm. Pfizer indicated a possible takeover in late June, after the company filed a Schedule 13D with the SEC. At that time, the parties entered into preliminary discussions.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Partial Acquisition
    • Payment Includes Cash for Equity

Related Companies